Fredun Pharmaceuticals Sees Strong FY26 Growth, Proposes Bonus and Dividend

Fredun Pharmaceuticals' standalone Profit After Tax (PAT) for FY 2025-26 surged by 59.59% to ₹33.21 crore, up from ₹20.81 crore in the previous fiscal.

Reader Takeaway: Strong profit growth and shareholder returns signal positive momentum.

What just happened

Fredun Pharmaceuticals reported a standalone Profit After Tax (PAT) of ₹33.21 crore for FY 2025-26, a significant increase from ₹20.81 crore in FY 2024-25. Total income rose by 40.08% to ₹639.12 crore.

The company also proposed a bonus issue of 2:1 and recommended a final dividend of 7% (₹0.70 per share). Authorized Share Capital is proposed to be increased from ₹10 crore to ₹50 crore.

Infomerics upgraded the company's credit rating to IVR BBB+ (Stable).

Why this matters

This performance indicates robust operational efficiency and effective cost management, leading to improved margins. The bonus issue and dividend payout signal management's confidence and commitment to shareholder value. The credit rating upgrade further bolsters investor confidence.

The backstory

The company has been focusing on strategic expansion and diversification into healthcare verticals. Investments in manufacturing facilities are underway to support future growth.

What changes now

Shareholders will benefit from the bonus issue, increasing their share count. The dividend provides immediate returns. The increased authorized capital will facilitate future expansion plans.

Risks to watch

As a pharmaceutical entity, Fredun faces inherent regulatory risks and stringent quality control requirements. Monitoring future borrowing and capital raising to fund growth is crucial to manage leverage.

Peer comparison

Fredun Pharma's growth in PAT and revenue aligns with positive trends in the broader pharmaceutical sector, which has seen consistent demand. However, specific margin improvements and corporate actions differentiate its performance.

Context metrics (time-bound)

• Total Income: Increased 40.08% to ₹639.12 crore in FY26 from ₹456.27 crore in FY25.
• EBITDA: Grew 72.05% to ₹94.79 crore in FY26 from ₹55.10 crore in FY25.
• PAT: Increased 59.59% to ₹33.21 crore in FY26 from ₹20.81 crore in FY25.
• EBITDA Margin: Improved to 14.83% in FY26 from 12.08% in FY25.
• PAT Margin: Improved to 5.20% in FY26 from 4.56% in FY25.

What to track next

Investors should watch the successful implementation of the bonus issue, the payout of the recommended dividend, and the progress of the company's expansion plans and diversification into new healthcare verticals.